Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer

British Medical Journal

Volumn 328, Issue 7431, 2004, Pages 81-84

  Renehan, Andrew G ^a   O'Dwyer, Sarah T ^a   Whynes, David K ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH SERVICE; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; UNITED KINGDOM;

COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 1642575951     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Office of National Statistics. Cancer statistics: registrations, series MB1 for 1999. www.statistics.gov.uk (accessed 18 Mar 2003).
2. Information and Statistics Division (ISD) Scotland. Cancer: facts and figures for 1999. www.show.scot.nhs.uk/isd (accessed 18 Mar 2003).
3. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002;324:813.
4. Jeffrey GM, Hickey BH, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. In: Cochrane Library, Issue 1. Oxford: Update Software, 2002.
5. Secco GB, Fardelli R, Gianquinto D, Bonfante P, Baldi E, Ravera G, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomised and controlled trial. Eur J Surg Oncol 2002;28:418-23.
6. Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg 1995;130:1062-7.
7. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma: randomized comparison with no follow-up. Dis Colon Rectum 1995;38:619-26.
8. Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998;114:7-14.
9. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998;41:1127-33.
10. Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 1997;84:666-9.
11. Department of Health NHS reference costs. www.doh.gov.uk/nhsexec/ refcosts.htm (accessed 18 Mar 2003).
12. Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, Sculpher M, et al. Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. BMJ 2001;323:423-5.
13. Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial. BMJ 2002;325:1135.
14. UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002;359:1291-300.
15. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
16. Fusai G, Davidson BR. Management of colorectal liver metastases. Colorectal Dis 2003;5:2-23.
17. Wanebo HJ, Antoniuk P, Koness RJ, Levy A, Vezeridis M, Cohen SI, et al. Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum 1999;42:1438-48.
18. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
19. UK Government Actuary's Department. Life tables. www.gad.uk/ policy_and_stats/life_tables.htm (accessed 18 Mar 2003).
20. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001;323:1300-3.
21. Torgerson D, Raftery J. Economics notes: discounting. BMJ 1999;319:914-5.
22. Virgo KS, Vernava AM, Longo WE, McKirgan LW, Johnson FE. Cost of patient follow-up after potentially curative colorectal cancer treatment. JAMA 1995;273:1837-41.
23. Norum J, Olsen JA. A cost-effectiveness approach to the Norwegian follow-up programme in colorectal cancer. Ann Oncol 1997;8:1081-7.
24. Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative cancer therapy: a critical review and economic analysis. J Gen Intern Med 1997;12:318-31.
25. Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 1998;228:59-63.
26. Beart RW Jr. Follow-up: does it work? Can we afford it? Surg Oncol Clin N Am 2000;9:827-34.
27. Van den Hout WB, van den Brink M, Stiggelbout AM, van de Velde CJH, Kievit J. Cost-effectiveness analysis of colorectal cancer treatments. Eur J Cancer 2002;38:953-63.
28. Renehan AG, Egger M, Saunders MP, Whynes D, O'Dwyer ST. Intensive follow-up after colorectal cancer. Recent successes and future challenges. In: Cunningham D, Topham C, Miles A, eds. The effective management of colorectal cancer, 4th ed. London: Aesculapius Medical Press, 2004.
29. Wang H, Karesen R, Hervik A, Thoresen SO. Mammography screening in Norway: results from the first screening round in four counties and cost-effectiveness of a modeled nationwide screening. Cancer Causes Control 2001;12:39-45.
30. Whynes DK, Neilson AR, Walker AR, Hardcastle JD. Faecal occult blood screening for colorectal cancer: is it cost-effective? Health Econ 1998;7:21-9.
31. Kjeldsen BJ, Thorsen H, Whalley D, Kronborg O. Influence of follow-up on health-related quality of life after radical surgery for colorectal cancer. Scand J Gastroenterol 1999;34:509-15.
32. National Institute for Clinical Excellence. A review of the evidence for the clinical and cost-effectiveness of ironotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. www.nice.org.uk (accessed 18 Mar 2003).
33. Frew E, Wolstenholme JL, Atkin W, Whynes DK. Estimating time and travel costs incurred in clinic based screening: flexible sigmoidoscopy screening for colorectal cancer. J Med Screen 1999;6:119-23. BMJ 2004;328:84-7